Improving treatment for Parkinson's disease: Harnessing photothermal and phagocytosis-driven delivery of levodopa nanocarriers across the blood-brain barrier

Scientists have created a new way to deliver levodopa, the main treatment for Parkinson’s disease, directly to the brain. This system also helps reduce a type of cell damage called oxidative stress, which plays a key role in the disease. In tests with mice, the treatment improved movement, lowered oxidative stress, and protected brain cells. Normally, levodopa has trouble reaching the brain because of the blood-brain barrier, a protective layer that blocks many substances. To solve this, researchers placed levodopa inside a protective capsule that shields it from being broken down too early. This capsule is designed to release levodopa only when it detects high levels of oxidative stress in the brain. The delivery system includes tiny gold rods that help temporarily open the blood-brain barrier when activated by a laser, making it easier for the treatment to reach the brain. The system also uses a special coating that helps it attach to the barrier and move into brain tissue. Unlike regular levodopa treatments, which can sometimes cause more oxidative stress, this system not only increased dopamine levels in the brain but also reduced the harmful effects of oxidative stress. Mice treated with this method had better movement, less damage to brain cells, and fewer signs of stress in their brains compared to those given standard treatments. This research, published in the Asian Journal of Pharmaceutical Sciences, shows promise for improving Parkinson’s treatment and may also help in treating other brain-related conditions. Scientists hope this approach could one day slow disease progression and improve the lives of people with Parkinson’s.